BACK vs. EVOK, STSS, SNES, FNCH, GOVX, GBNHF, HSCS, TCBP, VERO, and TCON
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Evoke Pharma (EVOK), Sharps Technology (STSS), SenesTech (SNES), Finch Therapeutics Group (FNCH), GeoVax Labs (GOVX), Greenbrook TMS (GBNHF), Heart Test Laboratories (HSCS), TC Biopharm (TCBP), Venus Concept (VERO), and TRACON Pharmaceuticals (TCON). These companies are all part of the "medical" sector.
Evoke Pharma (NASDAQ:EVOK) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
Evoke Pharma has a net margin of -116.75% compared to Evoke Pharma's net margin of -176.22%. Evoke Pharma's return on equity of -2,069.01% beat IMAC's return on equity.
Evoke Pharma received 360 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 62.18% of users gave Evoke Pharma an outperform vote while only 0.00% of users gave IMAC an outperform vote.
Evoke Pharma has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, IMAC has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
5.8% of IMAC shares are owned by institutional investors. 6.1% of Evoke Pharma shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Evoke Pharma has higher earnings, but lower revenue than IMAC. Evoke Pharma is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.
In the previous week, IMAC had 37 more articles in the media than Evoke Pharma. MarketBeat recorded 41 mentions for IMAC and 4 mentions for Evoke Pharma. IMAC's average media sentiment score of 0.70 beat Evoke Pharma's score of 0.22 indicating that Evoke Pharma is being referred to more favorably in the media.
Summary
Evoke Pharma beats IMAC on 9 of the 15 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
